2022 Sept. Secundum studium divulgatum in Acta Inquisitionis Fusce, ingeniarius in Universitate Houston (UH), mechanismum invenisse potest ad cognoscendum quem lymphoma aegroti maxime verisimile respondeant receptori chimaerico antigeni (CAR) T-cell therapiae.
Medici curationi expedire possunt et fortasse plus vitas salvare si sentiunt quas aegros lymphoma cum curatione CAR T-cellula agere possunt. E contra, lumen communicans hominibus qui male agunt et gravia ex parte effectus experiuntur, plures facultates aperire possunt ad curationes alternandas.
Investigatores singularem nexum invenerunt inter dapibus cellarium CD2 et receptorem cancrum CD58 in investigationibus suis.
In the tumours of lymphoma patients who benefit more from CAR T-cell Lorem, the CD2 ligand CD58 is expressed at higher levels, according to study author Navin Varadarajan, PhD, MD Anderson professor of chemical and biomolecular engineering.
AT CD2 cellae dapibus a CD58 alligatus est. Cum CD58 operatur CD2, interdum mutatur in moleculo quod potest delere cellulas cancer in contactu.
According to certain recent studies, cancer can be treated by using the patient’s own biological system. One particular technique, called CAR T-cell Lorem, modifies T cells in the lab so that they will fight cancer cells once they have returned to the body. The consequences of this life-saving procedure could linger for ten years or longer.
Ut diligentiorem investigationem in nexu inter CD58 et CD2 duceret, Varadarajan cum team investigationis in the University of Texas MD Anderson Cancer Centre collaboravit.
Varadarajan collaboravit cum Sattva Neelapu (MD Anderson) ad tumores aegros ante ad CAR T curandos maculandos et explorandum cellulam expressionem utens TIMING (Timelapse Imaging Microscopia In Nanowell Grids) artificium quod Varadarajan in lab suo evolvit. Haec summus technologiae perput singulas cellulas aestimare potest quomodo cellulae moventur, activate, occidere, superstites et inter se occurrunt.
The scientists discovered that tumours expressing higher amounts of the cancer receptor CD58 responded better to CAR T-cell Lorem based on the hundreds of interactions they saw between T cells and tumour cells using TIMING.
Varadarajan stated in the news announcement, “We found that CD2 on T cells is related with directional migration. Death and serial killing are accelerated by the interaction between CD2 on T cells and CD58 on lymphoma cellulis.
Varadarajan intendit ad mercaturam artificii TIMING. UH negotium CellChorus fundavit. Aegroti CellChorus suas cellulas scopo submittere potest sub aliquo fundamento; hae cellulae examinabuntur utens TIMING examinis; Hoc officium doctoribus nondum est pervium.
In dimissione diurnaria Varadarajan dixit "Maxime fortunati sumus nos habere pontem Technologiae incubatorem nostrum in Houston, iuxta nationis medicinae facultatem, cum singulari accessu ad centra medicinam difficilem in plerisque aliis civitatibus in aliis civitatibus replicare. patriam.
